Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice
Ibrutinib is a bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL). In addition to blocking B-cell receptor signaling and chemokine receptor-mediated pathways in CLL cells, that are known drivers of diseas...
| الحاوية / القاعدة: | Haematologica |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
Ferrata Storti Foundation
2020-03-01
|
| الوصول للمادة أونلاين: | https://haematologica.org/article/view/9685 |